Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Neoplasms 2Sarcoma, Ewing 1Osteosarcoma 1Neuroectodermal Tumors, Primitive, Peripheral 1Neuroblastoma 1Colorectal Neoplasms 1Carcinoma, Renal Cell 1Bone Neoplasms 1

Interventions

Filgrastim 20Etoposide 20Ifosfamide 19Cyclophosphamide 18Vincristine 13Radiotherapy 13Doxorubicin 13Peripheral Blood Stem Cell Transplantation 12Melphalan 12Carboplatin 10Busulfan 9Topotecan 8Temozolomide 8Magnetic Resonance Spectroscopy 8X-Rays 6Thiotepa 6Phantoms, Imaging 6Irinotecan 6Granulocyte Colony-Stimulating Factor 6Specimen Handling 5Nuclear Medicine Department, Hospital 5Biopsy 5trioctyl phosphine oxide 4Mesna 4Docetaxel 4Dactinomycin 4temsirolimus 3etoposide phosphate 3cixutumumab 3Neoadjuvant Therapy 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neuroectodermal Tumors, Primitive, Peripheral × robatumumab × Clear all
NCT00617890 2018-08-23

A Study to Determine the Activity of Robatumumab (SCH 717454) in Participants With Relapsed Osteosarcoma or Ewing's Sarcoma (MK-7454-002/P04720)

Merck Sharp & Dohme LLC

Phase 2 Terminated
219 enrolled 13 charts
Sarcoma

Sarcoma, Ewing, Osteosarcoma, Neuroectodermal Tumors, Primitive, Peripheral

Data powered by HemOnc (CC BY 4.0) Colophon âš¡